Background: Osteosarcoma is the most common primary bone malignancy of adolescents and young adults. Methods: We analyzed liver X receptor α (LXRα) mRNA expression in 16 pairs of human osteosarcoma tissues and adjacent noncancerous tissues. Moreover, we investigated LXRα's potential role in regulating cell proliferation in Saos-2 and U2OS cells. Results: We found that activation of LXRα, a member of nuclear receptor, was able to inhibit cell proliferation in Saos-2 and U2OS cells. At the molecular level, our results further revealed that expression of tumor suppressor gene, FoxO1, was up-regulated by LXRα activation. LXRα activates FoxO1 transcription through a direct binding on its promoter region. Conclusion: LXRα acts as a tumor suppressor for osteosarcoma, which may offer a new way in molecular targeting cancer treatment.
Introduction
Osteosarcoma is the most common primary bone malignant tumor. Similar to other tumors, osteosarcoma is a complicated disease with multi-genetic variations [1, 2] . Therefore, investigations on gene regulation networks are helpful for further understanding the mechanism governing the initiation and progression of osteosarcoma [3] .
Liver X Receptors (LXRα and LXRβ) are members of nuclear receptors initially isolated in the liver and activated by cholesterol derivatives, the oxysterols [4, 5] . LXRβ expression is accepted to be rather ubiquitous, while LXRα is more restricted and mainly expressed in liver, intestine, white adipose tissue and macrophages [3] [4] [5] . The fundamental role of LXRα is to control cholesterol homeostasis. Large amount of cholesterol ester rapidly accumulated in the liver in LXRα null mice fed a high cholesterol diet [6, 7] . Besides, these mice developed an impaired bile acid homeostasis due to a default in the expression of the cholesterol 7a-hydroxylase (Cyp7A1), a key enzyme essential in bile acid synthesis [6, 7] .
Recent studies have also suggested that LXRα plays important roles in the regulation of tumorigenesis. It was shown that LXRα could associate with Hepatitis B virus X protein (HBx), which represents an important mechanism explaining HBx-induced hepatic lipogenesis during HBV-associated hepatic carcinogenesis [8] . Besides, LXR was shown to suppress mRNA and (or) protein expression of Skp2, cyclin A2, cyclin D1 and estrogen receptor (ER) alpha, whereas it increased the p53 protein level and maintained the Rb protein in a hypophosphorylated active form in several human breast cancer cells lines [9, 10] . Moreover, LXRα suppressed proliferation in the colon cancer [11] . LXRα agonist treatment also reduced the percentage of the cell population in S-phase and caused G(1) cell cycle arrest in prostate cancer cells [12] [13] [14] . However, whether LXR affects osteosarcoma progression remains unknown.
Materials and Methods

Cell culture and tissue samples
Osteosarcoma cell lines were obtained from American Type Culture Collection (Rockville, MD). Cells were culture in Dulbecco's modified Eagle's medium (DMEM, Gibco, Beijing) supplemented with 10% fetal bovine serum (Gibco, Beijing). Tumor tissues and adjacent normal tissues were collected from routine therapeutic surgery at our department. All samples were obtained with informed consent and approved by the hospital institutional review board.
Real-time PCR
Total RNA from tissue samples and cell lines was isolated by TRIzol reagent. The extracted RNA was quantified using an ND-1000 spectrophotometer (Nanodrop, Wilmington), and complementary singlestrand DNA was synthesized using an Omniscript RT kit (Qiagen, Valencia). Real-time PCR was performed using a SYBR Green Premix Ex Taq (Takara) on Light Cycler 480 (Roche). The interested transcripts expression was normalized to GAPDH mRNA expression using the ΔCt method and the linearized ΔCt (i.e. 2-ΔCt) was used for comparative purposes. The primer sequences were available upon request.
Plasmid construction, transfection and Luciferase reporter assay
Human FoxO1 promoter was amplified from the human genomic DNA template and inserted into pGL4.15 basic vector (Promega). Mutant LXR binding motif was generated using a PCR mutagenesis kit (Toyobo). All the transient transfections were performed by Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. For luciferase reporter assays, cells were seeded in 24-well plates and transfected with the indicated plasmids. Luciferase activities were measured using the Dual Luciferase Reporter Assay System (Promega).
BrdU Assays
A cell proliferation enzyme-linked immunosorbent assay (BrdU kit; Beyotime) was used to analyze the incorporation of BrdU during DNA synthesis following the manufacturer's protocols. All experiments were performed in triplicate. Absorbance was measured at 450 nm in the Spectra Max 190 ELISA reader (Molecular Devices, Sunnyvale, CA).
Western blot
Cells or tissues were harvested and lysed with ice-cold lysis buffer (50 mM Tris-HCl, pH 6.8, 100 mM 2-ME, 2% w/v SDS, 10% glycerol). After centrifugation at 20000× g for 10 min at 4 °C, proteins in the supernatants were quantified and separated by 10% SDS PAGE, transferred to NC membrane. After blocking 
LXRα deficiency abolished the roles of T0901317 and 22(R)-hydroxycholesterol
Next, endogenous LXRα expression was silenced by small interfering RNA (siRNA) oligos in Saos-2 and U2OS cells ( Fig. 2A-2B) . As a result, T0901317 and 22(R)-hydroxycholesterol could not exert the anti-proliferative roles in the presence of siRNA oligos targeting LXRα (Fig. 2C-2D) , suggesting that the roles of two compounds rely on LXRα expression.
LXRα up-regulated expression of the cell-cycle inhibitors p21 and p27
As LXRα inhibited cell proliferation, we examined its functions on expression of the genes related to cell-cycle regulators, including the CDK inhibitors p27 and p21. Results from real-time PCR and western blot analysis suggested that expression of p27 and p21 were up-regulated in cells treated with T0901317 and 22(R)-hydroxycholesterol, compared to 
LXRα increased the expression of transcription factor FoxO1 in osterosarcoma cells
Previous studies have revealed that FOXO1 can transcriptionally regulate a series of genes relevant to the cell cycle, including p27 and p21 [15] . In parallel, we found that LXRα activation led to a significant up-regulation of FoxO1 in two osteosarcoma cells (Fig. 4A-4D) .
Next, we focused on the molecular mechanism of LXRα regulation of FoxO1 transcription. Sequence analysis showed that the promoter region of human FoxO1 gene contained a potential LXRα binding site (approximately between -528 and -515bp) (Fig.  5A) . Luciferase report assays showed that the transcriptional activity of wild-type FoxO1 promoter was dramatically up-regulated by LXRα, whereas the transcriptional activity was abolished in the promoter bearing a mutation in LXRα-binding sites (Fig. 5B) . Furthermore, our chromatin immunoprecipitaton (ChIP) assays showed that LXRα could uniquely bind to FoxO1 promoter (Fig. 5C) . Besides, the binding of LXRα to the FoxO1 promoter was also enhanced by T0901317 treatment (Fig. 5C ).
LXRα expression levels was reduced in osteosarcoma tissues
Finally, we examined whether the LXRα was differentially expressed in human osteosarcoma tissues. Its expression level was determined using real-time PCR and western blot in human osteosarcoma tissues and pair-matched adjacent noncancerous tissues. Our results demonstrated that the expression level of LXRα was significantly decreased in osteosarcoma tissues in comparison with the adjacent noncancerous tissues (Fig. 6A and  6B) . 
